touchONCOLOGY touchONCOLOGY
Breast Cancer, Gynaecological Cancers, Policy
Watch Time: 5 mins

Navigating HRT and cancer risk: PrEvCan | Celia Diez de los Rios

Copy Link
Published Online: Jun 7th 2023

This July, the PrEvCan campaign is dedicated to raising awareness about women’s cancer risk in connection with breastfeeding and hormone replacement therapy (HRT). 

Initiated by the European Oncology Nursing Society (EONS), and with ESMO as a key campaign partner, the PrEvCan – Cancer Prevention Across Europe – campaign, is aimed at reducing the burden of cancer. 

In support of this initiative, and to help improve the dialogue between patients and healthcare professionals, we had the pleasure of engaging in conversation with advanced oncology nurse practitioner, Celia Diez de los Rios (EONS Education Working Group Co-Chair). In this interview we discussed current knowledge regarding the link between HRT and the development of specific cancers. We also explored the available evidence relating to the impact of HRT on cancer risk, including the effects of different durations, formulations, and treatment regimens. Additionally, we discussed particular populations that may be more susceptible to the potential influence of HRT on cancer risk.

Questions

  1. What is the current evidence supporting the use of Hormone Replacement Therapy (HRT) for managing menopausal symptoms in women? (0:22)
  2. Based on recent clinical data, what does the research indicate about the relationship between HRT use and the risk of developing cancer? (1:06)
  3. Are there differences in cancer risk associated with different formulations and regimens of HRT? (2:01)
  4. Does the duration of HRT use impact the risk of developing cancer? (3:00)
  5. Are there specific populations or groups of women who may be more susceptible to the cancer risk associated with HRT? (3:25)
  6. What advice would you give to women experiencing menopausal symptoms who are considering or currently using HRT? (4:05)

Disclosures: Celia Diez de los Rios has nothing to disclose in relation to this video interview.

Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.

Additional resources

To learn more about the campaign, and download toolkits and videos to help you spread the PrEvCan messages visit: https://cancernurse.eu/prevcan/

Read the European Code Against Cancer – 12 ways to reduce your cancer risk

Related PrEvCan content

Related Videos In Policy
  • Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72